Information Provided By: 
Fly News Breaks for April 10, 2015
HTWR, THOR
Apr 10, 2015 | 08:37 EDT
Leerink raised its price target for Thoratec (THOR) to $50 after its survey of 37 U.S. physicians indicated adverse events, including stroke, for both HeartWare's (HTWR) HVAD and Thoratec's HeartMate II are not dramatically different in commercial use. The firm reiterates Outperform ratings on both stocks heading into next week's initial ENDURANCE data.
News For THOR;HTWR From the Last 2 Days
There are no results for your query THOR;HTWR
